Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study
: In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. Peripheral blood inflammatory biomarkers derived from routine laboratory parameters showed limited value in predicting pCR in this setting.
Authors
- Özgen Ahmet Yıldırım (ORCID: https://orcid.org/0000-0002-4139-067X)
- Erkan Erdur (ORCID: https://orcid.org/0000-0002-9123-2688)
- Berkan Karabuğa (ORCID: https://orcid.org/0000-0001-5357-7610)
- Ayşegül İlhan Güleşen
- Ferit Aslan (ORCID: https://orcid.org/0000-0002-9153-6921)
- Fatih Gürler (ORCID: https://orcid.org/0000-0003-0023-5793)
- Emrah Eraslan (ORCID: https://orcid.org/0000-0003-2497-5913)
- Salih Karatlı (ORCID: https://orcid.org/0000-0002-4237-1606)
- Merve Yalınkılıç
- İlknur Deliktaş Onur (ORCID: https://orcid.org/0000-0001-9884-5789)
- Hatime Arzu Yaşar
- Sıla Soylu Koçoğlu (ORCID: https://orcid.org/0000-0001-7121-8152)
- Ece Bilgic Koylu
- Fatih Yıldız
Institutions
- Ankara University (TR)
- Memorial Ankara Hospital (TR)
- Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR)
- Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR)
- Yüksek İhtisas Üniversitesi (TR)
- Gazi University (TR)
Publication Details
- Journal
- Medicina
- Published
- 2026-04-15
- DOI
- https://doi.org/10.3390/medicina62040763
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00